Cognition in patients treated with targeted therapy for chronic myeloid leukemia: A controlled comparison Journal Article


Authors: Hyland, K. A.; Eisel, S. L.; Hoogland, A. I.; Root, J. C.; Bowles, K.; James, B.; Nelson, A. M.; Booth-Jones, M.; Jacobsen, P. B.; Ahles, T. A.; Jim, H. S. L.; Gonzalez, B. D.
Article Title: Cognition in patients treated with targeted therapy for chronic myeloid leukemia: A controlled comparison
Abstract: This controlled comparison study evaluated objective and subjective cognitive function and their relationships with patient-reported symptoms (depression, fatigue, insomnia) in patients receiving tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and non-cancer controls. Patients with CML in chronic phase treated with the same oral TKI for ≥6 months (n = 90) and non-cancer controls (n = 87) completed a neurocognitive battery and self-report measures. Patients demonstrated worse overall neuropsychological performance (p =.05) and verbal memory (p =.02) compared to controls. Patients were not more likely to meet criteria for impaired cognitive performance compared to controls (ps>.26). Patients reported worse subjective global and domain-specific cognitive complaints and less satisfaction with cognitive function compared to controls (ps <.05). Patients also reported greater fatigue and insomnia symptoms (ps <.001). In both groups, greater fatigue, insomnia, and depressive symptoms were associated with worse subjective cognition (ps <.01). Longitudinal studies are needed to examine changes in cognitive function in patients before and during TKI treatment. © 2022 Informa UK Limited, trading as Taylor & Francis Group.
Keywords: fatigue; protein kinase inhibitor; chronic myeloid leukemia; protein kinase inhibitors; insomnia; cognition; leukemia, myelogenous, chronic, bcr-abl positive; complication; sleep initiation and maintenance disorders; humans; human
Journal Title: Leukemia and Lymphoma
Volume: 64
Issue: 2
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2023-01-01
Start Page: 415
End Page: 423
Language: English
DOI: 10.1080/10428194.2022.2148208
PUBMED: 36476293
PROVIDER: scopus
PMCID: PMC10305842
DOI/URL:
Notes: Article -- Export Date: 1 March 2023 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Tim A Ahles
    182 Ahles
  2. James Charles Root
    113 Root